Keji Pharmaceutical-B (02171) issued an announcement. On May 7, 2024, the company granted 260,000 share options to three share option grantees in accordance with the terms of the initial public offering after-sales share option plan, but only after acceptance by the share option grantor. The exercise price for which the share options were granted was HK$5.94 per share.
On May 7, 2024, the company granted 60,000 restricted share units to a restricted share unit grantor in accordance with the terms of the restricted share unit after sale of the initial public offering plan, subject to acceptance by the restricted share unit grantor.